Avodart contains dutasteride, a dual 5-alpha-reductase inhibitor used for adult men with moderate to severe benign prostatic hyperplasia (BPH). Its main benefit is gradual reduction of prostate-related urinary symptoms by lowering dihydrotestosterone (DHT), which can reduce prostate volume and improve urinary flow.
Avodart contains dutasteride, a dual 5-alpha-reductase inhibitor used for adult men with moderate to severe benign prostatic hyperplasia (BPH). Its main benefit is gradual reduction of prostate-related urinary symptoms by lowering dihydrotestosterone (DHT), which can reduce prostate volume and improve urinary flow.
Avodart contains dutasteride, a dual 5-alpha-reductase inhibitor. It is an oral capsule for adult men with moderate to severe benign prostatic hyperplasia (BPH), and it lowers dihydrotestosterone (DHT) to reduce prostate volume and improve urinary flow gradually.
Dutasteride is a 5-alpha-reductase enzyme inhibitor. The enzyme 5-alpha reductase converts testosterone into dihydrotestosterone, also called DHT or 5α-dihydrotestosterone. DHT is a potent androgen involved in the growth and maintenance of prostate tissue.
Avodart inhibits both major enzyme isoforms:
This dual inhibition distinguishes dutasteride from selective inhibitors that mainly target type 2 5-alpha-reductase. By blocking testosterone conversion in more than one tissue pathway, dutasteride produces a substantial reduction in circulating and intraprostatic DHT [2].
Lower DHT reduces androgen stimulation inside the prostate. Over time, the gland may become smaller, the pressure around the urethra may lessen, and urine may pass more freely. The improvement is gradual because the treatment changes prostate biology rather than simply relaxing smooth muscle.
Avodart is a urology medication for benign prostatic hyperplasia, a non-cancerous enlargement of the prostate that can restrict urine flow through the urethra. Dutasteride reduces the hormonal stimulation that maintains prostate tissue, so treatment is aimed at improving lower urinary tract symptoms over time rather than producing immediate relief.
BPH symptoms may include:
Avodart is used for moderate to severe BPH in adult men. Clinical goals include reducing prostate gland size, lowering the risk of acute urinary retention, reducing the likelihood of BPH-related surgery, and improving urinary flow measurements such as peak urinary flow rate [1].
Another common mistake is judging treatment by one symptom alone. Night-time urination can be affected by evening fluids, sleep apnoea, diabetes, diuretics, and bladder function, so urinary frequency may not track prostate size precisely.
Avodart is not intended for women. Dutasteride is contraindicated during pregnancy because 5-alpha-reductase inhibition can affect the development of external male genitalia in a male fetus.
Dutasteride is metabolised in the liver. Medicines that strongly inhibit CYP3A4 or P-glycoprotein may increase dutasteride exposure. Examples include certain azole antifungals, macrolide antibiotics, HIV medicines, and some calcium-channel blockers. The interaction risk depends on the specific medicine, dose, and duration.
Avodart is not for you if:
Pregnant women must not handle leaking or damaged dutasteride capsules. Dutasteride can be absorbed through the skin and may interfere with the development of male fetal genital organs.
The Canadian product information and Health Canada safety framework should guide the relevant deferral period [4].
Avodart can cause sexual and breast-related adverse reactions. The product information for dutasteride identifies reduced libido, erectile difficulties, ejaculation problems, and breast tenderness or enlargement among the reactions associated with treatment [3].
Possible adverse effects include:
Sexual adverse effects may appear during treatment and can continue for some time after discontinuation in some men. The persistence of symptoms varies between individuals, and the relationship may be influenced by BPH itself, age, cardiovascular health, diabetes, mood, and other medicines.
Breast changes deserve attention. New breast lumps, persistent pain, nipple discharge, or visible enlargement should be assessed promptly because these symptoms require clinical evaluation rather than self-monitoring alone.
Serious allergic reactions are uncommon but require urgent care if swelling of the face, lips, tongue, or throat affects breathing or swallowing.
| Treatment approach | Main action and clinical role |
|---|---|
| Dutasteride | Inhibits type 1 and type 2 5-alpha-reductase, lowers DHT, and gradually reduces prostate volume |
| Finasteride | Mainly inhibits type 2 5-alpha-reductase and supports gradual reduction of prostate-related obstruction |
| Alpha-blocker such as tamsulosin | Relaxes smooth muscle around the prostate and bladder neck, often giving earlier symptom improvement |
Dutasteride and finasteride are 5-alpha-reductase inhibitors. Dutasteride blocks both type 1 and type 2 enzymes, while finasteride has a narrower enzyme profile. The broader inhibition can produce a stronger reduction in DHT, though the clinical choice depends on the patient rather than enzyme coverage alone.
Alpha-blockers can be useful when rapid urinary symptom relief is needed. They do not shrink the prostate. They may cause dizziness, postural hypotension, nasal congestion, or ejaculation changes, so these effects matter when selecting treatment.
A combination of a 5-alpha-reductase inhibitor and an alpha-blocker may be considered for men with bothersome symptoms and a larger prostate. The combination addresses two mechanisms: smooth-muscle tone and prostate growth. It also exposes the patient to the adverse effects of both classes.
In clinical practice, doctors usually present dutasteride as a long-term prostate treatment rather than a quick symptom reliever. Men with a larger prostate often have more to gain from prostate-shrinking therapy, while men seeking rapid improvement may need a different or additional approach.
A urologist will also explain that symptom improvement and prostate shrinkage are related but not identical. A man may urinate more comfortably before a large reduction in prostate size is measurable. Another man may have a smaller prostate but persistent urgency caused by bladder overactivity.
PSA interpretation is a recurring clinical issue. Dutasteride lowers PSA, so a clinician needs the baseline value and the treatment duration when interpreting a later result. A rising PSA during treatment can require further investigation rather than simple reassurance.
One practical point is often missed: reduced ejaculation volume can be noticeable even when erection quality remains unchanged. Discussing this before treatment prevents the symptom from being mistaken for a new unrelated condition.
Dutasteride is generally stopped without a gradual taper because it does not produce the same withdrawal pattern as medicines that directly alter central nervous system activity. Its long half-life means that drug levels decline slowly after the final capsule. BPH symptoms may gradually return as DHT activity and prostate-related obstruction re-emerge. The 2024 European Medicines Agency product information describes the prolonged persistence of dutasteride in the body after discontinuation [5].
Avodart usually works gradually rather than providing same-day relief. Some urinary changes may be noticed during the first weeks, while the full prostate-related benefit can take several months. The response depends on prostate volume, baseline symptoms, bladder function, and whether another BPH treatment is used. Health Canada product information from 2023 supports using dutasteride as a longer-term treatment for BPH rather than judging it after only a few doses.
Dutasteride capsules can generally be taken with or without food. Taking the capsule at a consistent time can make the routine easier and reduce missed doses. The capsule should be swallowed whole rather than opened, chewed, or crushed. The 2024 EMA-approved product information describes oral administration without requiring a specific meal-dependent schedule.
A single dose contributes to prolonged exposure because dutasteride has a long elimination half-life. The clinical effect depends on regular treatment over time, not on taking an extra capsule when urinary symptoms flare. Drug levels decline slowly after stopping, and hormonal effects may persist after the last dose. WHO pharmacological information from 2023 on 5-alpha-reductase inhibition supports understanding dutasteride as a sustained systemic treatment rather than a short-acting urinary medicine.
Discuss liver disease, allergies, current medicines, fertility plans, sexual concerns, and any previous PSA results. The clinician should know whether you take an alpha-blocker, medicines that inhibit CYP3A4, or other treatments affecting blood pressure or sexual function. PSA interpretation requires awareness that dutasteride lowers PSA values. Health Canada guidance from 2023 places emphasis on medication history, pregnancy exposure precautions, and appropriate monitoring during treatment.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used Avodart for several months and noticed that starting urination became easier and the stream was stronger. Night-time bathroom trips also became less disruptive. The improvement was gradual, but it became clear when I compared my routine with the weeks before treatment.
Avodart helped with the weak flow that had been bothering me during the day. I did not notice a dramatic change at first, then the interruptions became less frequent after continued use. The capsules were easy to swallow whole.
My urinary symptoms improved, especially the urgency, but the change took longer than I expected. I also noticed lower sexual interest and discussed it with my doctor. The benefit was real, although the trade-off made the decision less straightforward.
I found that emptying my bladder felt easier after staying with treatment for a while. The improvement was practical rather than dramatic; I spent less time waiting for the stream to start and felt more comfortable during the day.
